← Leaderboards
Liise-Anne Pirofski
Yeshiva University
$20,784,118
Attributed
$20,784,118
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$20,784,118 · 8
By mechanism
R01$20,376,991 · 7
R56$407,127 · 1
Top collaborators
No co-investigators on record.
Most similar at Yeshiva University
Same institution · by research overlap
- Ekaterina Dadachova$3,442,959
- Bettina Fries$11,552,965
- Herbert Bernard Tanowitz$11,025,489
Others in their field
Top investigators on “Polysaccharides”
- Barton F Haynes · Duke University$271,280,523
- James C. Paulson · Scripps Research Institute$26,939,993
- George M Shaw · University Of Pennsylvania$26,084,324
- Arturo Casadevall · Johns Hopkins University$24,878,303
- Pamela J Bjorkman · California Institute Of Technology$23,198,758
- Ajit P Varki · University Of California San Diego$23,013,837
Research focus
PolysaccharidesVaccinesAntibodiesStreptococcus PneumoniaeMediatingPreventionGene ExpressionImmunityB-LymphocytesResponseHiv InfectionsLungGenesPreventIn VitroAntigensLinkImmunocompromised HostVaccine EfficacyAnti-Retroviral AgentsNovel StrategiesAntibody-Mediated ProtectionCryptococcus NeoformansMonoclonal Antibodies
Grant awards (53)
Antibodies, B cells and resistance to human cryptococcosis$532,469
R01 · FY2024 · AI · contact PI
Antibodies, B cells and resistance to human cryptococcosis$547,115
R01 · FY2023 · AI · contact PI
Antibodies, B cells and resistance to human cryptococcosis$177,490
R01 · FY2022 · AI · contact PI
Antibodies, B cells and resistance to human cryptococcosis$709,959
R01 · FY2021 · AI · contact PI
Antibody therapy for pneumococcal disease$417,500
R01 · FY2021 · AI · contact PI
Antibodies, B cells and resistance to human cryptococcosis$667,846
R01 · FY2020 · AI · contact PI
Antibody therapy for pneumococcal disease$417,500
R01 · FY2020 · AI · contact PI
Antibodies, B cells and resistance to human cryptococcosis$522,712
R01 · FY2019 · AI · contact PI
Antibody therapy for pneumococcal disease$302,982
R01 · FY2019 · AI · contact PI
Antibody therapy for pneumococcal disease$114,518
R01 · FY2019 · AI · contact PI
Antibody therapy for pneumococcal disease$417,500
R01 · FY2018 · AI · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$328,962
R01 · FY2018 · AG · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$171,014
R01 · FY2018 · AG · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$505,454
R01 · FY2017 · AG · contact PI
Antibody therapy for pneumococcal disease$417,500
R01 · FY2017 · AI · contact PI
B cell subsets and immunity to cryptococcosis$548,281
R01 · FY2016 · AI · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$505,454
R01 · FY2016 · AG · contact PI
B cell subsets and immunity to cryptococcosis$319,830
R01 · FY2015 · AI · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$266,639
R01 · FY2015 · AG · contact PI
B cell subsets and immunity to cryptococcosis$228,451
R01 · FY2015 · AI · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$223,652
R01 · FY2015 · AG · contact PI
B cell subsets and immunity to cryptococcosis$564,366
R01 · FY2014 · AI · contact PI
Effects of aging and HIV infection on the response to pneumococcal vaccine$519,532
R01 · FY2014 · AG · contact PI
B cell subsets and immunity to cryptococcosis$469,702
R01 · FY2013 · AI · contact PI
Antibody immunity to serotype 3 Streptococcus pneumoniae$317,046
R56 · FY2013 · AI · contact PI
Antibody immunity to serotype 3 Streptococcus pneumoniae$90,081
R56 · FY2013 · AI · contact PI
B cell subsets and immunity to cryptococcosis$534,858
R01 · FY2012 · AI · contact PI
Variable Gene Defects and Pneumococcal Susceptibility$415,000
R01 · FY2010 · AI · contact PI
Variable Gene Use and Pneumococcal Immunity in AIDS$391,357
R01 · FY2010 · AI · contact PI
Variable Gene Defects and Pneumococcal Susceptibility$415,000
R01 · FY2009 · AI · contact PI
Variable Gene Use and Pneumococcal Immunity in AIDS$395,309
R01 · FY2009 · AI · contact PI
Human Antibodies to Cryptococcus Neoformans$386,018
R01 · FY2009 · AI · contact PI
Variable Gene Use and Pneumococcal Immunity in AIDS$395,309
R01 · FY2008 · AI · contact PI
Human Antibodies to Cryptococcus Neoformans$386,018
R01 · FY2008 · AI · contact PI
Variable Gene Use and Pneumococcal Immunity in AIDS$402,965
R01 · FY2007 · AI · contact PI
Human Antibodies to Cryptococcus Neoformans$393,495
R01 · FY2007 · AI · contact PI
Variable Gene Use and Pneumococcal Immunity in AIDS$413,959
R01 · FY2006 · AI · contact PI
Human Antibodies to Crytococcus Neoformans$403,824
R01 · FY2006 · AI · contact PI
Human Antibodies to Cryptococcus Neoformans$411,042
R01 · FY2005 · AI
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITY$375,750
R01 · FY2005 · AI
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS$417,500
R01 · FY2004 · AI
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITY$375,750
R01 · FY2004 · AI
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS$417,500
R01 · FY2003 · AI
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITY$375,750
R01 · FY2003 · AI
HUMAN ANTIBODIES TO CRYPTOCOCCUS NEOFORMANS$339,179
R01 · FY2003 · AI
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITY$376,032
R01 · FY2002 · AI
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS$356,963
R01 · FY2002 · AI
HUMAN ANTIBODIES TO CRYPTOCOCCUS NEOFORMANS$332,479
R01 · FY2002 · AI
VARIABLE GENE DEFECTS AND PNEUMOCOCCAL SUSCEPTIBILITY$376,875
R01 · FY2001 · AI
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS$376,875
R01 · FY2001 · AI
HUMAN ANTIBODIES TO CRYPTOCOCCUS NEOFORMANS$325,974
R01 · FY2001 · AI
VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS$370,125
R01 · FY2000 · AI
HUMAN ANTIBODIES TO CRYPTOCOCCUS NEOFORMANS$319,657
R01 · FY2000 · AI